Scandion Oncology announces share purchase by member of the Board of Directors
Scandion Oncology, a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options today announced that a member of the Board of Directors has purchased shares in the company.Board member Nils Brünner has reported that he has bought 38.393 shares. This brings his total shareholding up to 304,944 shares. Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them. For further information please contact: Johnny Stilou, Acting CEO & CFO Phone: